8-KLeadership Changes

PFIZER INC 8-K Report, Executive Changes (Jul 27, 2023)

Filed July 27, 2023For Securities:PFE

Summary

Pfizer Inc. announced a significant restructuring of its Research and Development (R&D) organization, strategically elevating Oncology to a standalone unit. This move is directly linked to Pfizer's planned future investments in oncology, including the proposed acquisition of Seagen Inc. The new structure aims to enhance focus and agility within its cancer drug development pipeline. As part of this reorganization, Dr. Mikael Dolsten, Chief Scientific Officer and President of Pfizer R&D, will oversee consolidated early and late-stage development, while Dr. Chris Boshoff transitions to Chief Oncology Research and Development Officer. Importantly, Dr. William Pao, the former Chief Development Officer, will be leaving the company effective August 15, 2023, due to the elimination of his role. His departure is classified as an involuntary termination without cause, triggering specific severance and equity acceleration provisions as outlined in his employment agreements and company plans.

Key Highlights

  • 1Pfizer is restructuring its R&D organization, establishing Oncology as a distinct, stand-alone unit.
  • 2This strategic shift is driven by planned future investments in Oncology, including the proposed acquisition of Seagen Inc.
  • 3Dr. Chris Boshoff has been appointed Chief Oncology Research and Development Officer, EVP.
  • 4Dr. Mikael Dolsten, CSO and President of R&D, will now lead the consolidated early and late-stage development efforts.
  • 5Dr. William Pao, Chief Development Officer, EVP, is leaving Pfizer effective August 15, 2023, as his role is eliminated.
  • 6Dr. Pao's departure is an involuntary termination without cause, entitling him to accelerated vesting of unvested awards, severance pay (one year's base salary and target bonus), and continued welfare benefits for two years.
  • 7Severance is contingent on Dr. Pao executing a release of claims and adhering to restrictive covenants.

Frequently Asked Questions

Pfizer is restructuring its R&D organization to create a standalone unit for Oncology. This is a strategic move to align with planned future investments in the oncology space, including the proposed acquisition of Seagen Inc., and to enhance focus and agility in developing cancer treatments.

Dr. Chris Boshoff will lead the new standalone Oncology R&D unit as Chief Oncology Research and Development Officer. Dr. Mikael Dolsten will oversee the consolidated early and late-stage development for the rest of the R&D organization. Dr. William Pao's role as Chief Development Officer is being eliminated, and he will depart the company on August 15, 2023.

Dr. Pao's departure is an involuntary termination without cause. Under his employment terms, he will receive accelerated vesting of his unvested sign-on awards (cash, RSUs, PSSP contributions), a severance package equivalent to one year's base salary and target bonus, and two years of continued welfare benefits. He will also receive a pro-rata 2023 bonus and prorated equity awards, settled according to plan terms. These benefits are subject to his execution of a release of claims and continued compliance with restrictive covenants.

The R&D restructuring, particularly the creation of a standalone Oncology unit, is directly linked to Pfizer's planned future investments in oncology and the proposed acquisition of Seagen Inc. This organizational change aims to better integrate and leverage the capabilities and pipeline that the Seagen acquisition is expected to bring.